Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
Retinoid (differentiating agent)
Tretinoin (ATRA)
Vesanoid · ATRA
The drug that turned APL from lethal to curable — but blast maturation can unleash a capillary-leak storm and AKI.
ModerateRetinoid (differentiating agent) · approved 1995
Acute promyelocytic leukemia (APL)
Signature kidney injury
Prerenal / Hemodynamic AKI
Representative incidence25%
Differentiation (retinoic acid) syndrome — the main route to AKI — occurs in roughly 2–37% of APL patients depending on criteria and prophylaxis (commonly cited around 25%); acute renal failure is part of its defining end-organ spectrum.
Source: Woods & Norsworthy, Cancers 2023 (2–37% across series)
Toxicity fingerprint
Tap a signature to trace where it strikes the nephron.
0%incidence
SeverityModerate
ReversibilityReversible
Evidence0 refs
Nephron map
Vasculature / EndotheliumGlomerular & peritubular capillaries
Proximal Tubule
Distal Tubule / Collecting Duct
Prerenal / Hemodynamic AKI
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Mechanism of kidney injury
Differentiating promyelocytes release inflammatory cytokines (and express adhesion molecules) causing a systemic capillary-leak syndrome with hypotension, third-spacing and tissue edema; the resulting hemodynamic compromise produces prerenal AKI that can progress to ischemic ATN. Pulmonary leukostasis/hyperleukocytosis and concurrent tumor lysis can compound the injury.
Clinical presentation
Fever, dyspnea/hypoxia, pulmonary infiltrates, peripheral edema, weight gain >5 kg, hypotension, pleural/pericardial effusion and acute renal failure (differentiation syndrome). A rising WBC during induction is characteristic.
Onset
Usually within the first 1–3 weeks of induction (bimodal: first week and third week).
Reversibility
Reversible
Anticancer mechanism
All-trans retinoic acid binds the ligand-binding domain of the PML-RARA fusion receptor, relieving its transcriptional repression and degrading the fusion oncoprotein to release the differentiation block — driving promyelocytic blasts to terminally mature. With arsenic trioxide it forms the chemo-free backbone of acute promyelocytic leukemia (APL) therapy.
Management
Start dexamethasone (10 mg IV q12h) immediately when differentiation syndrome is suspected; supportive hemodynamics, diuresis for fluid overload, oxygen. Temporarily hold ATRA for severe/refractory syndrome and resume once resolved.
Risk factors
- High or rising WBC (hyperleukocytosis)
- Bulky disease
- Concurrent infection
- Delayed corticosteroids
- High baseline creatinine
Prevention
- Prophylactic/early corticosteroids (e.g., prednisone/dexamethasone) in high-WBC patients
- Cytoreduction for hyperleukocytosis
- TLS prophylaxis with hydration and urate-lowering
- Close clinical/weight/oxygenation monitoring during induction
Note · Renal injury is a manifestation of differentiation syndrome and fluid shifts rather than direct tubular toxicity. ATRA is also a recognized therapeutic and prophylactic differentiator, so the clinical art is treating the syndrome without abandoning the cure.
Clinical depth
Renal dose adjustment
No established renal dose adjustment; standard induction is 45 mg/m²/day. Dose interruptions are driven by differentiation syndrome, pseudotumor cerebri and hepatotoxicity rather than CrCl.
Dialyzability & ESKD dosing
Not characterized; ATRA is highly protein-bound and hepatically metabolized (and autoinduces its own metabolism), so it is not expected to be appreciably dialyzed. Dialysis, if needed, treats the AKI/fluid overload, not drug levels.
Differential diagnosis
Differentiation syndrome vs sepsis/pneumonia (overlapping fever, infiltrates, hypotension), fluid overload, and pulmonary hemorrhage from APL coagulopathy. Weight gain, effusions and rising WBC favor the syndrome; prerenal/differentiation AKI is distinguished from tumor-lysis crystal nephropathy by the urate/phosphate profile.
Monitoring
- Daily weight, oxygenation and symptom assessment for differentiation syndrome during induction
- WBC trend (rising count heralds the syndrome and tumor-lysis risk)
- Tumor-lysis labs (uric acid, potassium, phosphate, calcium, creatinine)
- Coagulation parameters (APL coagulopathy/DIC accompanies induction)
Key trials & series
- Lo-Coco et al., NEJM 2013 — APL0406 (ATRA + arsenic trioxide vs ATRA-chemotherapy; established the chemo-free standard)
- Woods & Norsworthy (Woods AC et al.), Cancers 2023 — FDA review quantifying differentiation-syndrome incidence and renal failure
Clinical pearls
- At the first hint of differentiation syndrome, give dexamethasone immediately — do not wait for confirmation; renal failure is part of the syndrome.
- A rising WBC during ATRA induction is expected blast maturation but signals differentiation-syndrome and tumor-lysis risk.
- The AKI is hemodynamic (capillary leak), not direct tubulotoxicity — manage the syndrome and the kidney recovers.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Injury signatures
Prerenal / Hemodynamic AKIAcute Tubular Necrosis
Beyond the kidney
Class-level context for the major non-renal toxicities of retinoid (differentiating agent)s.
Pulmonary
Pneumonitis, ILD, effusions, hypertension
- Differentiation syndrome
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
- QT prolongation
Evidence
7 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkRetinoic acid and arsenic trioxide for acute promyelocytic leukemia.Lo-Coco F et al. · N Engl J Med 2013 · PMID 23841729APL0406 landmark phase 3: ATRA + arsenic trioxide as the chemo-free standard; context for differentiation-syndrome/renal risk.PMIDDifferentiation Syndrome in Acute Leukemia: APL and Beyond.Woods AC et al. · Cancers (Basel) 2023 · PMID 37835461FDA review: APL differentiation-syndrome incidence (2–37%), acute renal failure in its spectrum, and management.PMIDDifferentiation syndrome in acute promyelocytic leukaemia.Stahl M, Tallman MS · Br J Haematol 2019 · PMID 31410848Focused review listing acute renal failure among defining features; steroid treatment and prophylaxis strategy.PMIDThe differentiation syndrome in patients with acute promyelocytic leukemia: experience of the PETHEMA group and review of the literature.Montesinos P, Sanz MA · Mediterr J Hematol Infect Dis 2011 · PMID 22220256Large cohort/review describing capillary leak leading to acute renal failure and dexamethasone management.PMIDHow I treat acute myeloid leukemia with differentiation therapy.Issa GC et al. · Blood 2025 · PMID 38976876Practical management of differentiation syndrome (incl. renal insufficiency) across ATRA/ATO and newer agents.PMIDDifferentiation Syndrome, a Side Effect From the Therapy of Acute Promyelocytic Leukemia.Reyhanoglu G et al. · Cureus 2020 · PMID 33447473Case report of ATRA differentiation syndrome with acute renal failure and capillary leak.PMIDEfficacy and the Adverse Effects of Oral Versus Intravenous Arsenic for Acute Promyelocytic Leukemia: A Meta-Analysis of Randomized-Controlled Studies.Sasijareonrat N et al. · Technol Cancer Res Treat 2020 · PMID 32583728Quantifies differentiation syndrome and renal toxicity within ATRA-based APL regimens.
Related agents
Other agents sharing the same signature kidney injury.